Photocure ASA
OSE:PHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Photocure ASA
Common Shares Outstanding
Photocure ASA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Common Shares Outstanding
kr26.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Common Shares Outstanding
kr44.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Common Shares Outstanding
kr24m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Common Shares Outstanding
kr2.2B
|
CAGR 3-Years
501%
|
CAGR 5-Years
209%
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
Common Shares Outstanding
kr610k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Common Shares Outstanding?
Common Shares Outstanding
26.6m
NOK
Based on the financial report for Dec 31, 2025, Photocure ASA's Common Shares Outstanding amounts to 26.6m NOK.
What is Photocure ASA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
2%
Over the last year, the Common Shares Outstanding growth was -2%. The average annual Common Shares Outstanding growth rates for Photocure ASA have been -1% over the past three years , and 2% over the past ten years .
